---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-027339"
form_type: "8-K/A"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:57:04.746202+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma discloses separation terms for departing CFO Andrew Hindman

## Summary
- Separation agreement includes lump sum of 24 weeks base salary and 100% of 2022 target cash bonus.
- Company to pay up to 9 months COBRA premiums.
- 20,000 performance-based RSUs vested (performance criteria met).
- Hindman eligible for change in control severance if change in control within 3 months after Dec 31, 2022.

## SEC filing metadata
- accession: 0001104659-23-027339
- form_type: 8-K/A
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923027339/0001104659-23-027339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923027339/tm238017d4_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-027339
- JSON: https://secwatch.observer/filing/0001104659-23-027339.json
- Plain text: https://secwatch.observer/filing/0001104659-23-027339.txt

## Key facts
- Executive change
  Andrew Hindman departed as Chief Financial Officer at Theravance Biopharma, Inc..
  - Action: separated
  - Role: Chief Financial Officer
  source text: On January 10, 2023, Theravance Biopharma US, Inc., a wholly owned subsidiary of the Company (“Theravance Biopharma US”), and Mr. Hindman entered into a separation agreement and release of claims (the “Separation Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923027339/0001104659-23-027339-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.